Abstract
This article provides a practical review of the diagnosis and management of angle closure induced by psychotropic agents, including tricyclic antidepressants, antipsychotics and anticonvulsants. Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors and antipsychotics may trigger angle closure by influencing pupil configuration through adrenergic, anticholinergic, serotonergic or dopaminergic mechanisms. Patients with narrow iridocorneal angles are at risk, and these are more common in people with hypermetropia (near-sightedness), older people and individuals with an Asian background. These patients may benefit from a laser peripheral iridotomy, either prophylactically or to relieve an acute angle-closure episode. An idiosyncratic reaction to medications such as topiramate may lead to angle closure through an alternate mechanism, leading to a uveal effusion. Ophthalmological review may be considered prior to commencing medications in high-risk patients.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs40263-020-00790-w/MediaObjects/40263_2020_790_Fig1_HTML.jpg)
Similar content being viewed by others
References
Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127–41.
Congdon NG, Friedman DS. Angle-closure glaucoma: impact, etiology, diagnosis, and treatment. Curr Opin Ophthalmol. 2003;14(2):70–3.
Razeghinejad M, Myers J, Katz L. Iatrogenic glaucoma secondary to medications. Am J Med. 2011;124(1):20–5.
Khurana AK, Khurana B, Khurana AK. Drug-induced angle-closure glaucoma. J Curr Glaucoma Pract. 2012;6(1):6–8.
Lachkar Y, Bouassida W. Drug-induced acute angle-closure glaucoma. Curr Opin Ophthalmol. 2007;18(2):129–33.
Razeghinejad M, Pro M, Katz L. Non-steroidal drug-induced glaucoma. Eye. 2011;25(8):971–80.
Lee GC, Tam CP, Danesh-Meyer HV, Myers JS, Katz LJ. Bilateral angle-closure glaucoma induced by sulphonamide-derived medications. Clin Exp Ophthalmol. 2007;35(1):55–8.
Fraunfelder F, Fraunfelder F, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2004;111(1):109–11.
Richa S, Yazbek J-C. Ocular adverse effects of common psychotropic agents. CNS Drugs. 2010;24(6):501–26.
Levy J, Yagev R, Petrova A, Lifshitz T. Topiramate-induced bilateral angle-closure glaucoma. Can J Ophthalmol. 2006;41(2):221–5.
Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 2001;119(11):1721–3.
Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of topiramate-induced acute-onset myopia and angle-closure glaucoma. Am J Ophthalmol. 2004;137(1):193–5.
Abtahi M-A, Abtahi S-H, Fazel F, Roomizadeh P, Etemadifar M, Jenab K, et al. Topiramate and the vision: a systematic review. Clin Ophthalmol (Auckland, NZ). 2012;6:117.
Leung D, Leung H, Baig N, Kwan P, Kwong Y, Wong K, et al. Topiramate and asymptomatic ocular angle narrowing: a prospective pilot study. Eye. 2009;23(11):2079–81.
Ozturk BT, Genc E, Tokgoz M, Kerimoglu H, Genc BO. Ocular changes associated with topiramate. Curr Eye Res. 2011;36(1):47–52.
Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Inflamm. 2011;19(1):86–8.
Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132(1):112–4.
Etminan M, Maberley D, Mikelberg FS. Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol. 2012;153(5):827–30.
Ho J-D, Keller JJ, Tsai C-Y, Liou S-W, Chang C-J, Lin H-C. Topiramate use and the risk of glaucoma development: a population-based follow-up study. Am J Ophthalmol. 2013;155(2):336-341.e1.
Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas. Drug Saf. 2003;26(11):749–67.
Ritch R, Krupin T, Henry C, Kurata F. Oral imipramine and acute angle-closure glaucoma. Arch Ophthalmol. 1994;112(1):67–8.
Schlingemann R, Smit A, Lunel HV, Hijdra A. Amaurosis fugax on standing and angle-closure glaucoma with clomipramine. The Lancet. 1996;347(8999):465.
Subak-Sharpe I, Low S, Nolan W, Foster PJ. Pharmacological and environmental factors in primary angle-closure glaucoma. Br Med Bull. 2010;93(1):125–43.
Ahmad S. Fluoxetine and glaucoma. DICP. 1991;25(4):436.
Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications. CNS Drugs. 2004;18(8):475–84.
Bennett H, Wyllie A. Paroxetine and acute angle-closure glaucoma. Eye. 1999;13(5):691–2.
Eke T, Bates A. Acute angle-closure glaucoma associated with paroxetine. BMJ Br Med J. 1997;314(7091):1387.
Kirwan JF, Subak-Sharpe IAN, Teimory M. Bilateral acute angle-closure glaucoma after administration of paroxetine. Br J Ophthalmol. 1997;81(3):252.
Browning AC, Reck AC, Chisholm LH, Nischal KK. Acute angle-closure glaucoma presenting in a young patient after administration of paroxetine. Eye. 2000;14(3):406–8.
Lewis CF. Acute angle-closure glaucoma and paroxetine. J Clin Psychiatry. 1997;58:123–4.
Jiménez-Jiménez FJ, Ortí-Pareja M, Zurdo JM. Aggravation of glaucoma with fluvoxamine. Ann Pharmacother. 2001;35(12):1565–6.
Massaoutis P, Goh D, Foster P. Bilateral symptomatic angle-closure associated with a regular dose of citalopram, an SSRI antidepressant. Br J Ophthalmol. 2007;91(8):1086–7.
Croos R, Thirumalai S, Hassan S, Davis JDR. Citalopram associated with acute angle-closure glaucoma: case report. BMC Ophthalmol. 2005;5(1):23.
Adverse Drug Reactions Advisory Committee. Australian Adverse Drug Reactions Bulletin. 2001. p. 3.
Yang MC, Lin KY. Drug-induced acute angle-closure glaucoma: a review. J Curr Glaucoma Pract. 2019;13(3):104–9.
Shifera AS, Leoncavallo A, Sherwood M. Probable association of an attack of bilateral acute angle-closure glaucoma with duloxetine. Ann Pharmacother. 2014;48(7):936–9.
Ng B, Sanbrook GMC, Malouf AJ, Agarwal SA. Venlafaxine and bilateral acute angle-closure glaucoma. Med J Aust. 2002;176(5):241.
Ezra D, Storoni M, Whitefield L. Simultaneous bilateral acute angle-closure glaucoma following venlafaxine treatment. Eye. 2006;20(1):128–9.
Denis P, Charpentier D, Berros P, Touameur S. Bilateral acute angle-closure glaucoma after dexfenfluramine treatment. Ophthalmologica. 1995;209(4):223–4.
Lee JTL, Skalicky SE, Lin M-L. Drug-induced myopia and bilateral angle-closure secondary to Zolmitriptan. J Glaucoma. 2017;26(10):954–6.
de Guzman MHP, Thiagalingam S, Ong PY, Goldberg I. Bilateral acute angle-closure caused by supraciliary effusions associated with venlafaxine intake. Med J Aust. 2005;182(3):121–3.
Chen H-Y, Lin C-L, Lai S-W, Kao C-H. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016;77(6):e692–6.
Symes RJ, Etminan M, Mikelberg FS. Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol. 2015;133(10):1187–9.
Zelefsky JR, Fine HF, Rubinstein VJ, Hsu IS, Finger PT. Escitalopram-induced uveal effusions and bilateral angle-closure glaucoma. Am J Ophthalmol. 2006;141(6):1144–7.
Raj S, Kaur M, Srinivasarao K, Thattaruthody F, Kaushik S, Pandav SS. Mirtazapine-induced bilateral secondary angle-closure in a female. GMS Ophthalmol Cases. 2020;10:Doc29-Doc.
Seitz DP, Campbell RJ, Bell CM, Gill SS, Gruneir A, Herrmann N, et al. Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults. J Clin Psychopharmacol. 2012;32(3):403–7.
Achiron A, Aviv U, Mendel L, Burgansky-Eliash Z. Acute angle-closure glaucoma precipitated by olanzapine. Int J Geriatr Psychiatry. 2015;30(10):1101–2.
Shen E, Farukhi S, Schmutz M, Mosaed S. Acute angle-closure glaucoma associated with aripiprazole in the setting of plateau iris configuration. J Glaucoma. 2018;27(2):e40–3.
He M, Jiang Y, Huang S, Chang DS, Munoz B, Aung T, et al. Laser peripheral iridotomy for the prevention of angle-closure: a single-centre, randomised controlled trial. Lancet. 2019;393(10181):1609–18.
Rauscher FM, Parrish RK. Atypical angle-closures. Curr Opin Ophthalmol. 2008;19(2):107–14.
Parthasarathi S, Myint K, Singh G, Mon S, Sadasivam P, Dhillon B. Bilateral acetazolamide-induced choroidal effusion following cataract surgery. Eye. 2007;21(6):870–2.
Mancino R, Varesi C, Cerulli A, Aiello F, Nucci C. Acute bilateral angle-closure glaucoma and choroidal effusion associated with acetazolamide administration after cataract surgery. J Cataract Refract Surg. 2011;37(2):415–7.
Cole KL, Wang EE, Aronwald RM. Bilateral acute angle-closure glaucoma in a migraine patient receiving topiramate: a case report. J Emerg Med. 2012;43(2):e89–91.
Willett MC, Edward DP. Refractory topiramate-induced angle-closure glaucoma in a man: a case report. J Med Case Rep. 2011;5(1):33.
Rhee DJ, Ramos-Esteban JC, Nipper KS. Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol. Am J Ophthalmol. 2006;141(6):1133–4.
Zalta AH, Smith RT. Peripheral iridoplasty efficacy in refractory topiramate-associated bilateral acute angle-closure glaucoma. Arch Ophthalmol. 2008;126(11):1603–5.
Parikh R, Parikh S, Das S, Thomas R. Choroidal drainage in the management of acute angle-closure after topiramate toxicity. J Glaucoma. 2007;16(8):691–3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Neeranjali S. Jain, Claire W. Ruan, Shanil R. Dhanji, and Richard Symes have no conflicts of interest that are directly relevant to the content of this article.
Funding
No funding was used to assist with the preparation of this manuscript.
Author contributions
NSJ primary manuscript author, literature review and editing. CWR editing. SRD literature review and editing. RS conceptualization, supervisor and editing.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Rights and permissions
About this article
Cite this article
Jain, N.S., Ruan, C.W., Dhanji, S.R. et al. Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management. CNS Drugs 35, 283–289 (2021). https://doi.org/10.1007/s40263-020-00790-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-020-00790-w